Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmX TechnologiesASX:PHX 38 Receivables Turnover is 3.35 as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 38/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 660 Healthcare Providers & Services companies, PharmX Technologies ranks worse than 55.76% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PharmX Technologies's Revenue for the
six
months ended in Dec. 2025 was A$3.82 Mil. PharmX Technologies's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$1.14 Mil.
Hence, PharmX Technologies's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.35.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PharmX Technologies Receivables Turnover Related Terms
PharmX Technologies Receivables Turnover Historical Data
* Premium members only.
The historical data trend for PharmX Technologies's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PHX vs VEEV, BTSG, TEM: Receivables Turnover Comparison
For the Health Information Services subindustry, PharmX Technologies's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmX Technologies Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PharmX Technologies's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmX Technologies (ASX:PHX) has a Receivables Turnover of 3.35 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PharmX Technologies and its competitors. According to the industry distribution chart, PharmX Technologies ranks #368 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 55.8%.
Is PharmX Technologies' Receivables Turnover too high?
PharmX Technologies' current Receivables Turnover is 3.35. The Healthcare Providers & Services industry median Receivables Turnover is 7.75. PharmX Technologies' value of 3.35 is 56.7% below this industry median. Based on the distribution chart, PharmX Technologies ranks #368 out of 660 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PharmX Technologies has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Receivables Turnover compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #368 out of 660 companies for Receivables Turnover. This places PharmX Technologies in the lower half of its industry. The industry median Receivables Turnover is 7.75. PharmX Technologies' value of 3.35 is 56.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.75, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmX Technologies's current Receivables Turnover of 3.35 is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PharmX Technologies and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current Receivables Turnover is 3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.12 — trading 64.3% above its estimated fair value. The current Receivables Turnover is 3.35 and 56.7% below the Healthcare Providers & Services industry median of 7.75. PharmX Technologies' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Receivables Turnover is 3.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.12 is trading 64.3% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
Receivables Turnover: 3.35
GF Value™: A$0.07 vs. price of A$0.12 (64.3% above fair value)
Industry Position: 56.7% below the Healthcare Providers & Services median (#368 of 660)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
38GF Score
Get the complete analysis for ASX:PHX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
